Atreca to Present at Upcoming Virtual Investor Conferences
April 06 2021 - 4:30PM
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company
focused on developing novel therapeutics generated through a unique
discovery platform based on interrogation of the active human
immune response, today announced that it will participate in the
following upcoming virtual investor conferences:
20th Annual Needham
Virtual Healthcare ConferenceTuesday, April 13,
2021Presentation time: 1:30 p.m. EDT
Canaccord Genuity Horizons in Oncology Virtual
ConferenceThursday, April 15, 2021Panel time: 4:00 p.m.
EDT
A live audio webcast of the Needham presentation can be accessed
through the Events & Presentations section of the company's
website at ir.atreca.com. An archived replay will be available on
the company's website for 90 days following the live
presentation.
About Atreca, Inc. Atreca is a
biopharmaceutical company developing novel antibody-based
immunotherapeutics generated by its differentiated discovery
platform. Atreca’s platform allows access to an unexplored
landscape in oncology through the identification of unique
antibody-target pairs generated by the human immune system during
an active immune response against tumors. These antibodies provide
the basis for first-in-class therapeutic candidates, such as our
lead product candidate ATRC-101. A Phase 1b study evaluating
ATRC-101 in multiple solid tumor cancers is currently enrolling
patients. For more information on Atreca, please visit
www.atreca.com.
Forward-Looking StatementsCertain statements in
this press release regarding our strategy and future plans,
including statements regarding the development of ATRC-101 and our
clinical and regulatory plans and the timing thereof, constitute
forward-looking statements under the Private Securities Litigation
Reform Act of 1995. These forward-looking statements include, but
are not limited to, statements about our plans, objectives,
representations and contentions and are not historical facts. Our
actual results may differ materially from those indicated in these
forward-looking statements due to risks and uncertainties related
to the initiation, timing, progress and results of our research and
development programs, preclinical studies, clinical trials, and
regulatory submissions, the activity of ATRC-101 or potential
future candidates once administered in human subjects, and the
implementation of our strategic plans for our business,
technologies, and current or potential future product candidates.
More information on these risks and potential factors that could
affect our business and financial results is included in our
filings with the U.S. Securities and Exchange Commission (SEC) and
available on the SEC’s website at www.sec.gov, including in our
most recently filed Annual Report on Form 10-K and Quarterly Report
on Form 10-Q and subsequent filings. Investors are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date of this release, and we undertake no
obligation to update any forward-looking statement in this press
release, except as required by law.
ContactsAtreca, Inc.Herb CrossChief Financial
Officerinfo@atreca.comInvestors:Alex Gray,
650-779-9251agray@atreca.com
Media:Sheryl Seapy, 213-262-9390sseapy@w2ogroup.com
Source: Atreca, Inc.
Atreca (NASDAQ:BCEL)
Historical Stock Chart
From Sep 2024 to Oct 2024
Atreca (NASDAQ:BCEL)
Historical Stock Chart
From Oct 2023 to Oct 2024